First Trust Advisors’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.32M Buy
163,459
+780
+0.5% +$25.6K ﹤0.01% 1397
2025
Q4
$5.16M Buy
162,679
+10,380
+7% +$312K ﹤0.01% 1382
2025
Q3
$3.58M Buy
+152,299
New +$2.61M ﹤0.01% 1548

Other funds holding STOK

First Trust Advisors's STOK Position: Q1 2026 in Review

First Trust Advisors increased its Stoke Therapeutics (STOK) stake by 0.48% in Q1 2026, buying an estimated $25.6K and bringing the position to 163,459 shares worth $5.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

First Trust Advisors first reported a position in STOK in Q3 2025 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • First Trust Advisors held 163,459 shares of Stoke Therapeutics worth $5.32M as of Q1 2026.
  • First Trust Advisors bought 780 Stoke Therapeutics shares in Q1 2026, an estimated $25.6K.
  • Stoke Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q1 2026, its #1397 holding.
  • First Trust Advisors first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.